Naptumomab estafenatox
- Generic Name
- Naptumomab estafenatox
- Drug Type
- Biotech
- CAS Number
- 676258-98-3
- Unique Ingredient Identifier
- 93T929W6LC
- Background
Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
First Patient Enrolled in Phase Ib/II Trial of Tasquinimod for Treatment-Resistant Myelofibrosis
• Active Biotech has initiated patient enrollment in a Phase Ib/II clinical trial evaluating tasquinimod for myelofibrosis patients who are refractory or ineligible for JAK2 inhibitor treatment.
• The open-label study will assess tasquinimod's safety and efficacy as monotherapy, with a primary endpoint targeting 35% reduction in spleen volume after 24 weeks of treatment.
• The trial, sponsored by HOVON and financially supported by Oncode Institute, will be conducted across study centers in the Netherlands and Germany, addressing a significant unmet medical need.
IN8bio's INB-100 Shows Promising Phase 1 Results with Zero Relapses in High-Risk AML Patients
• IN8bio's allogeneic gamma-delta T cell therapy INB-100 demonstrated remarkable efficacy with no relapses in AML patients over a median follow-up of 20.1 months.
• The therapy achieved impressive survival metrics with 90.9% progression-free survival and 100% overall survival at one year, surpassing historical outcomes.
• INB-100 exhibited a favorable safety profile with no cytokine release syndrome, neurotoxicity, or treatment-related deaths, positioning it as a potential breakthrough in post-transplant care.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath